Eli Lilly and Company completed a major multi-billion-dollar all-cash acquisition of Novartis Animal Health, integrating its extensive global portfolio of veterinary treatments, vaccines, and R&D facilities into its Elanco animal health division. This strategic transaction significantly expanded Elanco's market presence across worldwide livestock and companion animal sectors, positioning the combined entity as a leading global competitor in the veterinary pharmaceutical space.